Traitomic bets on ‘gene-editing outcomes without gene editing’ after €20m Series A

As pressure grows on agriculture to improve productivity, resilience and sustainability simultaneously, Traitomic is betting that many customers will be less concerned with whether a trait was gene edited and more interested in whether it can reach the market quickly, gain regulatory acceptance and deliver a commercial return.
As pressure grows on agriculture to improve productivity, resilience and sustainability simultaneously, Traitomic is betting that many customers will be less concerned with whether a trait was gene edited and more interested in whether it can reach the market quickly, gain regulatory acceptance and deliver a commercial return. (Traitomic)

Danish biotech start-up Traitomic has raised €20m to expand its FIND-IT platform, which identifies useful genetic variants in conventionally bred crops and microorganisms without gene editing. The company believes the approach offers breeders and food companies a commercially practical route to developing new traits while avoiding some of the regulatory and market challenges associated with gene-edited products

Danish biotechnology company Traitomic has secured €20 million in a Series A funding round led by Sofinnova Partners, with backing from the Export and Investment Fund of Denmark (EIFO), Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures.

The investment marks the company’s first external funding since spinning out of Carlsberg and will support international expansion as well as the continued development of its scientific and commercial capabilities.

Finding the right mutation rather than creating it

Unlike technologies such as CRISPR that introduce targeted genetic changes, FIND-IT identifies naturally occurring genetic variants within conventionally bred populations.

Traitomic argues that this enables companies to develop improved traits while following a conventional breeding pathway that is broadly accepted across global markets.

“Ultimately, our customers are not buying technology. They are trying to solve commercial challenges,” co-founder and chief executive Gustav Hambraeus told AgNavigator.

“Traitomic provides a route to develop improved biological traits in a way that is broadly accepted and commercially practical across global markets.

“We believe finding the right genetic change is often more valuable than creating it, because it enables improvements in plants and microorganisms through a broadly applicable, conventional route that fits all commercial, regulatory and consumer expectations.”

The company says the platform has now delivered 116 customer-requested traits across 32 organisms, ranging from crops and food ingredients to industrial microorganisms.

An alternative to gene editing rather than a replacement

Hambraeus stressed that FIND-IT is not intended to compete directly with gene-editing technologies.

“Gene editing can be an excellent option in some situations, and FIND-IT is not intended to replace it. However, many companies are looking for solutions that combine precision with a conventional development route. In those cases, Traitomic can offer an attractive alternative.”

He argued that many customers are increasingly focused on the most commercially viable route to market rather than the underlying science.

“Factors such as applicability, freedom to operate, regulatory pathways, consumer acceptance, and development timelines can all influence which route is most attractive.”

The approach could prove particularly appealing to plant breeders, food manufacturers and retailers that want access to improved crop genetics while avoiding some of the commercial uncertainties that continue to surround genetically modified and gene-edited products in parts of the world.

Demand spans agriculture, food and biotechnology

Traitomic’s customer base stretches well beyond crop breeding.

According to Hambraeus, customers are using the platform to develop traits linked to productivity, resilience, quality and sustainability across agriculture, food production and industrial biotechnology.

While plant breeders may be interested in drought tolerance, disease resistance and input efficiency, food companies are seeking improvements in flavour, nutrition and shelf life, while biotechnology firms are focused on microbial performance and production efficiency.

“In agriculture, we have seen particularly strong activity in legumes, oilseeds and specialty crops, including lupin, pea, bean, oat and canola,” he said.

The company has already established development platforms for several of these crops, allowing customers to begin proof-of-concept and trait-validation projects more quickly.

From years of breeding to weeks of trait discovery

Traitomic claims FIND-IT can substantially shorten the trait-development process compared with conventional breeding approaches.

“For established FIND-IT platforms, individual traits can often be identified, validated and handed over within four to eight weeks,” Hambraeus said.

The company said its first trait-development project in quinoa was completed in less than 10 months from project initiation.

Rather than simply accelerating discovery, Traitomic argues the platform can reduce time to market by introducing improvements directly into commercially relevant crop varieties and microbial strains.

“Our objective is not only to identify a useful genetic change, but to deliver biological material that can move efficiently into a customer’s development, breeding or commercialisation pipeline,” Hambraeus said.

Co-founder and chief executive Gustav Hambraeus: “We believe finding the right genetic change is often more valuable than creating it, because it enables improvements in plants and microorganisms through a broadly applicable, conventional route that fits all commercial, regulatory and consumer expectations.”
Co-founder and chief executive Gustav Hambraeus: “We believe finding the right genetic change is often more valuable than creating it, because it enables improvements in plants and microorganisms through a broadly applicable, conventional route that fits all commercial, regulatory and consumer expectations.” (Traitomic)

Commercial deployment still to come for many traits

Despite having delivered 116 traits, Traitomic acknowledged that many have yet to reach the market.

Hambraeus said trait delivery and commercial deployment should be viewed as separate milestones, with customers typically taking responsibility for downstream testing, scale-up and commercialisation.

“In plants, that process often takes time, meaning many of the traits we have delivered are currently progressing through customers’ development pipelines rather than already being visible in the market,” he said.

However, he added that some microbial applications have already progressed into commercial products because development cycles tend to be shorter.

From Carlsberg barley research to broader bioeconomy ambitions

FIND-IT was originally developed within Carlsberg Research Laboratory as part of efforts to improve barley for brewing.

According to Hambraeus, the original objectives included both agronomic improvements, such as yield and climate resilience, and traits designed to make brewing more efficient and sustainable.

Today, however, barley is no longer a strategic focus for Traitomic.

“Traitomic is not working with barley, and is not working with brewers,” he said.

Instead, the company is pursuing opportunities across a much broader range of agricultural, food and industrial biotechnology applications.

For investors, that breadth is central to the company’s appeal.

“Traitomic has demonstrated something that is rare in biological innovation: the ability to develop commercially relevant traits across a broad range of organisms and applications,” said Michael Krel, partner at Sofinnova Partners.